Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis : A worldwide study
Copyright © 2021 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved..
BACKGROUND & AIMS: Corticosteroids are the only effective therapy for severe alcohol-associated hepatitis (AH), defined by a model for end-stage liver disease (MELD) score >20. However, there are patients who may be too sick to benefit from therapy. Herein, we aimed to identify the range of MELD scores within which steroids are effective for AH.
METHODS: We performed a retrospective, international multicenter cohort study across 4 continents, including 3,380 adults with a clinical and/or histological diagnosis of AH. The main outcome was mortality at 30 days. We used a discrete-time survival analysis model, and MELD cut-offs were established using the transform-the-endpoints method.
RESULTS: In our cohort, median age was 49 (40-56) years, 76.5% were male, and 79% had underlying cirrhosis. Median MELD at admission was 24 (19-29). Survival was 88% (87-89) at 30 days, 77% (76-78) at 90 days, and 72% (72-74) at 180 days. A total of 1,225 patients received corticosteroids. In an adjusted-survival-model, corticosteroid use decreased 30-day mortality by 41% (hazard ratio [HR] 0.59; 0.47-0.74; p <0.001). Steroids only improved survival in patients with MELD scores between 21 (HR 0.61; 0.39-0.95; p = 0.027) and 51 (HR 0.72; 0.52-0.99; p = 0.041). The maximum effect of corticosteroid treatment (21-30% survival benefit) was observed with MELD scores between 25 (HR 0.58; 0.42-0.77; p <0.001) and 39 (HR 0.57; 0.41-0.79; p <0.001). No corticosteroid benefit was seen in patients with MELD >51. The type of corticosteroids used (prednisone, prednisolone, or methylprednisolone) was not associated with survival benefit (p = 0.247).
CONCLUSION: Corticosteroids improve 30-day survival only among patients with severe AH, especially with MELD scores between 25 and 39.
LAY SUMMARY: Alcohol-associated hepatitis is a condition where the liver is severely inflamed as a result of excess alcohol use. It is associated with high mortality and it is not clear whether the most commonly used treatments (corticosteroids) are effective, particularly in patients with very severe liver disease. In this worldwide study, the use of corticosteroids was associated with increased 30-day, but not 90- or 180-day, survival. The maximal benefit was observed in patients with an MELD score (a marker of severity of liver disease; higher scores signify worse disease) between 25-39. However, this benefit was lost in patients with the most severe liver disease (MELD score higher than 51).
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:75 |
---|---|
Enthalten in: |
Journal of hepatology - 75(2021), 5 vom: 24. Nov., Seite 1026-1033 |
Sprache: |
Englisch |
---|
Links: |
---|
Anmerkungen: |
Date Completed 08.02.2022 Date Revised 15.02.2022 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.jhep.2021.06.019 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM327139269 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM327139269 | ||
003 | DE-627 | ||
005 | 20231225200120.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.jhep.2021.06.019 |2 doi | |
028 | 5 | 2 | |a pubmed24n1090.xml |
035 | |a (DE-627)NLM327139269 | ||
035 | |a (NLM)34166722 | ||
035 | |a (PII)S0168-8278(21)00439-6 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Arab, Juan Pablo |e verfasserin |4 aut | |
245 | 1 | 0 | |a Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis |b A worldwide study |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 08.02.2022 | ||
500 | |a Date Revised 15.02.2022 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2021 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved. | ||
520 | |a BACKGROUND & AIMS: Corticosteroids are the only effective therapy for severe alcohol-associated hepatitis (AH), defined by a model for end-stage liver disease (MELD) score >20. However, there are patients who may be too sick to benefit from therapy. Herein, we aimed to identify the range of MELD scores within which steroids are effective for AH | ||
520 | |a METHODS: We performed a retrospective, international multicenter cohort study across 4 continents, including 3,380 adults with a clinical and/or histological diagnosis of AH. The main outcome was mortality at 30 days. We used a discrete-time survival analysis model, and MELD cut-offs were established using the transform-the-endpoints method | ||
520 | |a RESULTS: In our cohort, median age was 49 (40-56) years, 76.5% were male, and 79% had underlying cirrhosis. Median MELD at admission was 24 (19-29). Survival was 88% (87-89) at 30 days, 77% (76-78) at 90 days, and 72% (72-74) at 180 days. A total of 1,225 patients received corticosteroids. In an adjusted-survival-model, corticosteroid use decreased 30-day mortality by 41% (hazard ratio [HR] 0.59; 0.47-0.74; p <0.001). Steroids only improved survival in patients with MELD scores between 21 (HR 0.61; 0.39-0.95; p = 0.027) and 51 (HR 0.72; 0.52-0.99; p = 0.041). The maximum effect of corticosteroid treatment (21-30% survival benefit) was observed with MELD scores between 25 (HR 0.58; 0.42-0.77; p <0.001) and 39 (HR 0.57; 0.41-0.79; p <0.001). No corticosteroid benefit was seen in patients with MELD >51. The type of corticosteroids used (prednisone, prednisolone, or methylprednisolone) was not associated with survival benefit (p = 0.247) | ||
520 | |a CONCLUSION: Corticosteroids improve 30-day survival only among patients with severe AH, especially with MELD scores between 25 and 39 | ||
520 | |a LAY SUMMARY: Alcohol-associated hepatitis is a condition where the liver is severely inflamed as a result of excess alcohol use. It is associated with high mortality and it is not clear whether the most commonly used treatments (corticosteroids) are effective, particularly in patients with very severe liver disease. In this worldwide study, the use of corticosteroids was associated with increased 30-day, but not 90- or 180-day, survival. The maximal benefit was observed in patients with an MELD score (a marker of severity of liver disease; higher scores signify worse disease) between 25-39. However, this benefit was lost in patients with the most severe liver disease (MELD score higher than 51) | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Observational Study | |
650 | 4 | |a Research Support, N.I.H., Extramural | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a MELD | |
650 | 4 | |a Maddrey discriminant function | |
650 | 4 | |a alcohol | |
650 | 4 | |a alcohol-associated liver disease | |
650 | 4 | |a alcoholic hepatitis | |
650 | 4 | |a alcoholic liver disease | |
650 | 4 | |a cirrhosis | |
650 | 4 | |a corticosteroids | |
650 | 4 | |a steroids | |
650 | 7 | |a Steroids |2 NLM | |
700 | 1 | |a Díaz, Luis Antonio |e verfasserin |4 aut | |
700 | 1 | |a Baeza, Natalia |e verfasserin |4 aut | |
700 | 1 | |a Idalsoaga, Francisco |e verfasserin |4 aut | |
700 | 1 | |a Fuentes-López, Eduardo |e verfasserin |4 aut | |
700 | 1 | |a Arnold, Jorge |e verfasserin |4 aut | |
700 | 1 | |a Ramírez, Carolina A |e verfasserin |4 aut | |
700 | 1 | |a Morales-Arraez, Dalia |e verfasserin |4 aut | |
700 | 1 | |a Ventura-Cots, Meritxell |e verfasserin |4 aut | |
700 | 1 | |a Alvarado-Tapias, Edilmar |e verfasserin |4 aut | |
700 | 1 | |a Zhang, Wei |e verfasserin |4 aut | |
700 | 1 | |a Clark, Virginia |e verfasserin |4 aut | |
700 | 1 | |a Simonetto, Douglas |e verfasserin |4 aut | |
700 | 1 | |a Ahn, Joseph C |e verfasserin |4 aut | |
700 | 1 | |a Buryska, Seth |e verfasserin |4 aut | |
700 | 1 | |a Mehta, Tej I |e verfasserin |4 aut | |
700 | 1 | |a Stefanescu, Horia |e verfasserin |4 aut | |
700 | 1 | |a Horhat, Adelina |e verfasserin |4 aut | |
700 | 1 | |a Bumbu, Andreea |e verfasserin |4 aut | |
700 | 1 | |a Dunn, Winston |e verfasserin |4 aut | |
700 | 1 | |a Attar, Bashar |e verfasserin |4 aut | |
700 | 1 | |a Agrawal, Rohit |e verfasserin |4 aut | |
700 | 1 | |a Haque, Zohaib Syed |e verfasserin |4 aut | |
700 | 1 | |a Majeed, Muhammad |e verfasserin |4 aut | |
700 | 1 | |a Cabezas, Joaquín |e verfasserin |4 aut | |
700 | 1 | |a García-Carrera, Inés |e verfasserin |4 aut | |
700 | 1 | |a Parker, Richard |e verfasserin |4 aut | |
700 | 1 | |a Cuyàs, Berta |e verfasserin |4 aut | |
700 | 1 | |a Poca, Maria |e verfasserin |4 aut | |
700 | 1 | |a Soriano, German |e verfasserin |4 aut | |
700 | 1 | |a Sarin, Shiv K |e verfasserin |4 aut | |
700 | 1 | |a Maiwall, Rakhi |e verfasserin |4 aut | |
700 | 1 | |a Jalal, Prasun K |e verfasserin |4 aut | |
700 | 1 | |a Abdulsada, Saba |e verfasserin |4 aut | |
700 | 1 | |a Higuera-de la Tijera, María Fátima |e verfasserin |4 aut | |
700 | 1 | |a Kulkarni, Anand V |e verfasserin |4 aut | |
700 | 1 | |a Rao, P Nagaraja |e verfasserin |4 aut | |
700 | 1 | |a Guerra Salazar, Patricia |e verfasserin |4 aut | |
700 | 1 | |a Skladaný, Lubomir |e verfasserin |4 aut | |
700 | 1 | |a Bystrianska, Natália |e verfasserin |4 aut | |
700 | 1 | |a Prado, Veronica |e verfasserin |4 aut | |
700 | 1 | |a Clemente-Sanchez, Ana |e verfasserin |4 aut | |
700 | 1 | |a Rincón, Diego |e verfasserin |4 aut | |
700 | 1 | |a Haider, Tehseen |e verfasserin |4 aut | |
700 | 1 | |a Chacko, Kristina R |e verfasserin |4 aut | |
700 | 1 | |a Cairo, Fernando |e verfasserin |4 aut | |
700 | 1 | |a de Sousa Coelho, Marcela |e verfasserin |4 aut | |
700 | 1 | |a Romero, Gustavo A |e verfasserin |4 aut | |
700 | 1 | |a Pollarsky, Florencia D |e verfasserin |4 aut | |
700 | 1 | |a Restrepo, Juan Carlos |e verfasserin |4 aut | |
700 | 1 | |a Castro-Sanchez, Susana |e verfasserin |4 aut | |
700 | 1 | |a Toro, Luis G |e verfasserin |4 aut | |
700 | 1 | |a Yaquich, Pamela |e verfasserin |4 aut | |
700 | 1 | |a Mendizabal, Manuel |e verfasserin |4 aut | |
700 | 1 | |a Garrido, Maria Laura |e verfasserin |4 aut | |
700 | 1 | |a Narvaez, Adrián |e verfasserin |4 aut | |
700 | 1 | |a Bessone, Fernando |e verfasserin |4 aut | |
700 | 1 | |a Marcelo, Julio Santiago |e verfasserin |4 aut | |
700 | 1 | |a Piombino, Diego |e verfasserin |4 aut | |
700 | 1 | |a Dirchwolf, Melisa |e verfasserin |4 aut | |
700 | 1 | |a Arancibia, Juan Pablo |e verfasserin |4 aut | |
700 | 1 | |a Altamirano, José |e verfasserin |4 aut | |
700 | 1 | |a Kim, Won |e verfasserin |4 aut | |
700 | 1 | |a Araujo, Roberta C |e verfasserin |4 aut | |
700 | 1 | |a Duarte-Rojo, Andrés |e verfasserin |4 aut | |
700 | 1 | |a Vargas, Victor |e verfasserin |4 aut | |
700 | 1 | |a Rautou, Pierre-Emmanuel |e verfasserin |4 aut | |
700 | 1 | |a Issoufaly, Tazime |e verfasserin |4 aut | |
700 | 1 | |a Zamarripa, Felipe |e verfasserin |4 aut | |
700 | 1 | |a Torre, Aldo |e verfasserin |4 aut | |
700 | 1 | |a Lucey, Michael R |e verfasserin |4 aut | |
700 | 1 | |a Mathurin, Philippe |e verfasserin |4 aut | |
700 | 1 | |a Louvet, Alexandre |e verfasserin |4 aut | |
700 | 1 | |a García-Tsao, Guadalupe |e verfasserin |4 aut | |
700 | 1 | |a González, José Alberto |e verfasserin |4 aut | |
700 | 1 | |a Verna, Elizabeth |e verfasserin |4 aut | |
700 | 1 | |a Brown, Robert S |e verfasserin |4 aut | |
700 | 1 | |a Roblero, Juan Pablo |e verfasserin |4 aut | |
700 | 1 | |a Abraldes, Juan G |e verfasserin |4 aut | |
700 | 1 | |a Arrese, Marco |e verfasserin |4 aut | |
700 | 1 | |a Shah, Vijay H |e verfasserin |4 aut | |
700 | 1 | |a Kamath, Patrick S |e verfasserin |4 aut | |
700 | 1 | |a Singal, Ashwani K |e verfasserin |4 aut | |
700 | 1 | |a Bataller, Ramon |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Journal of hepatology |d 1993 |g 75(2021), 5 vom: 24. Nov., Seite 1026-1033 |w (DE-627)NLM012604372 |x 1600-0641 |7 nnns |
773 | 1 | 8 | |g volume:75 |g year:2021 |g number:5 |g day:24 |g month:11 |g pages:1026-1033 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jhep.2021.06.019 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 75 |j 2021 |e 5 |b 24 |c 11 |h 1026-1033 |